Navigation Links
Corcept Therapeutics Announces Phase 3 Study Evaluating Corlux for,Psychotic Major Depression Misses Primary Endpoint

ulation and often require lengthy and expensive hospital stays. There is no FDA-approved treatment for PMD.

About Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing drugs for treating severe psychiatric and neurological diseases. Corcept's lead product, CORLUX, is in Phase 3 clinical trials for treating the psychotic features of PMD. The drug is administered orally to PMD patients once per day for seven days. CORLUX, a potent GR-II antagonist, appears to reduce the effects of the elevated and abnormal release patterns of cortisol seen in PMD. The company has also initiated a proof-of-concept study to evaluate the ability of CORLUX to mitigate weight gain associated with the use of olanzapine. For more information, please visit www.corcept.com.

Forward-looking Statements

Statements made in this news release – other than statements of historical fact – are forward-looking statements. These include information relating to Corcept’s PMD clinical development program and the timing of the completion of Phase 3 trials. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied here. For example, there can be no assurances on the efficacy, safety, enrollment completion or success of clinical trials; the regulatory process or regulatory approvals; commercial success; in addition, trial timetables may not be accurate. Risk factors are explained in the company's SEC filings, all of which are available from its Web site (www.corcept.com) or from the SEC's Web site (www.sec.gov). The company does not have any intention or duty to update forward-looking statements made in this news release.


CONTACT:
Fred Kurland
Chief Financial Officer
Corcept Therapeutics
650-327-3270





Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/22/2014)... July 22, 2014  PuraMed BioScience®, Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced today that ... Troop Aid. "We are pleased to ... , CEO and Chairman of PuraMed BioScience. "Research ... combat zones experience migraines much more frequently than ...
(Date:7/22/2014)... July 22, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that the U.S. Food and ... Drug, or IND, application.  Such clearance will permit Galmed ... in the United States for ...
(Date:7/22/2014)... 22, 2014 /PRNewswire-iReach/ -- Reproductive Medicine Associates of ... ), a nationally and internationally-recognized leader in providing ... assistance, is pleased to announce a new collaboration with ... Programs to recognize the sacrifices made by veterans and ... Corps Program will allow qualifying veterans and the spouses ...
Breaking Medicine Technology:PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3
(Date:7/22/2014)... 2014 The 2014 Warrior-Family Symposium ... Reagan Building and International Trade Center in Washington, ... and Civilian Communities,” will be held from 8:30 ... a.m.) and cohosted by the Military Officers Association ... Association (NDIA). USAA is the Executive Sponsor of ...
(Date:7/22/2014)... By Steven Reinberg ... -- Two treatments that break up blood clots deep in ... of death risk. However, one results in a greater risk ... the cost of the other treatment, a new study finds. ... deep vein thrombosis (DVT) -- is blood-thinning medications and compression ...
(Date:7/22/2014)... minimally invasive hysterectomy using electric power morcellation, uterine cancers ... time of the procedure, according to a study published ... this procedure, in which the uterus is fragmented into ... malignancies. , Despite the commercial availability of electric power ... of malignancy at the time of electric power morcellation ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... disorders may share certain pathogenic mechanisms with cancer, according ... researcher Linda Kusner, Ph.D. , published in ... shifting work shows that the very same inhibitors of ... in cells that produce autoimmune diseases. Henry Kaminski, ... the GW School of Medicine and Health Sciences (SMHS), ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... and product launch in Southern California is an important stride to ... ... Americans -, TORRANCE, Calif., Sept. 24 Tokyo-based consumer,products company ... first mainstream market in the U.S.,This fall, the probiotic dairy drink will ...
... New findings from researchers at Wake Forest University ... with kidney failure can develop a rare tightening and ... lungs and heart. , Reporting in the October ... suggest a possible explanation for why some patients on ...
... 24 When the Deficit Reduction Act of,2005 ... state Medicaid programs,must demonstrate compliance with the requirement ... or risk losing federal,funding. Under tremendous pressure ... - 90 days, some states already are requiring ...
... Assessment of Impact Underway; Updated Results to Be ... Congress Considers Legislation to Ease Requirements, WASHINGTON, ... of the impact of Medicaid documentation requirements enacted ... of Public Health,and Health Services (GW SPHHS) compiled ...
... Inc. (NYSE: PRX ) invites investors and the,general ... update on the company,s,business strategy and results from 8:30 ... to the live webcast, visit the company,s website homepage ... link. A replay of the,meeting will be available approximately ...
... MetLife Foundation will,begin the next phase of its ... cooperation with the nonprofit Partnership,for a Drug-Free America(R) ... The radio campaign is backed by web resources ... features radio messages, in both English and Spanish,which ...
Cached Medicine News:Health News:Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market 2Health News:New study suggests cause of debilitating skin condition 2Health News:ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 3Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 4Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 2Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 3Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 4
... The CKX microscopes utilize the ... visibility and operability in cell ... cost-effective inverted microscope suited to ... of fields--from tissue culture and ...
Continuous rocking motion graphic display....
Stainless steel lockable wall display for up to 12 frames....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: